| Antiemetics: American Society of Clinical Oncology clinical practice guideline update PJ Hesketh, MG Kris, E Basch, K Bohlke, SY Barbour, RA Clark-Snow, ... Journal of Clinical Oncology 35 (28), 3240-3261, 2017 | 738* | 2017 |
| Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia SB Dusetzina, AN Winn, GA Abel, HA Huskamp, NL Keating J Clin Oncol 32 (4), 306-311, 2014 | 471 | 2014 |
| Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ... Journal of Clinical Oncology 32 (30), 3436, 2014 | 267 | 2014 |
| Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review SB Dusetzina, AS Higashi, ER Dorsey, R Conti, HA Huskamp, S Zhu, ... Medical care 50 (6), 466, 2012 | 197 | 2012 |
| Linking data for health services research: a framework and instructional guide SB Dusetzina, S Tyree, AM Meyer, A Meyer, L Green, WR Carpenter | 123 | 2014 |
| Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010 CF Garfield, ER Dorsey, S Zhu, HA Huskamp, R Conti, SB Dusetzina, ... Academic pediatrics 12 (2), 110-116, 2012 | 123 | 2012 |
| Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia AN Winn, NL Keating, SB Dusetzina Journal of Clinical Oncology 34 (36), 4323, 2016 | 105 | 2016 |
| Sorafenib effectiveness in advanced hepatocellular carcinoma HK Sanoff, YK Chang, JL Lund, BH O'Neil, SB Dusetzina The oncologist 21 (9), 1113-1120, 2016 | 105 | 2016 |
| Antiemetics: ASCO guideline update PJ Hesketh, MG Kris, E Basch, K Bohlke, SY Barbour, RA Clark-Snow, ... Journal of Clinical Oncology 38 (24), 2782-2797, 2020 | 104 | 2020 |
| Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014 SB Dusetzina JAMA oncology 2 (7), 960-961, 2016 | 103 | 2016 |
| Financial relationships with industry among National Comprehensive Cancer Network guideline authors AP Mitchell, EM Basch, SB Dusetzina JAMA oncology 2 (12), 1628-1631, 2016 | 101 | 2016 |
| Financial toxicity in adults with cancer: adverse outcomes and noncompliance TG Knight, AM Deal, SB Dusetzina, HB Muss, SK Choi, JT Bensen, ... Journal of Oncology Practice 14 (11), e665-e673, 2018 | 97 | 2018 |
| Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States WV Padula, RA Larson, SB Dusetzina, JF Apperley, R Hehlmann, ... Journal of the National Cancer Institute 108 (7), djw003, 2016 | 97 | 2016 |
| Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR* D BN Gaynes, SB Dusetzina, AR Ellis, RA Hansen, JF Farley, WC Miller, ... Journal of clinical psychopharmacology 32 (1), 114-119, 2012 | 88 | 2012 |
| The project data sphere initiative: accelerating cancer research by sharing data AK Green, KE Reeder-Hayes, RW Corty, E Basch, MI Milowsky, ... The oncologist 20 (5), 464-e20, 2015 | 81 | 2015 |
| Making medicines affordable: a national imperative National Academies of Sciences, Engineering, and Medicine National Academies Press, 2018 | 70 | 2018 |
| Trends in inpatient and outpatient hysterectomy and oophorectomy rates among commercially insured women in the United States, 2000-2014 KM Doll, SB Dusetzina, W Robinson JAMA surgery 151 (9), 876-877, 2016 | 66 | 2016 |
| Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019 SB Dusetzina, HA Huskamp, NL Keating Jama 321 (20), 2025-2028, 2019 | 61 | 2019 |
| Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending SB Dusetzina, RM Conti, LY Nancy, PB Bach JAMA internal medicine 177 (8), 1185-1188, 2017 | 61 | 2017 |
| Mind the gap: Why closing the doughnut hole is insufficient for increasing Medicare beneficiary access to oral chemotherapy SB Dusetzina, NL Keating Journal of Clinical Oncology 34 (4), 375, 2016 | 58 | 2016 |
Ethan BaschUniversity of North CarolinaVerified email at med.unc.edu
